A Phase II/III Study of Sargramostim

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

October 25, 2021

Study Completion Date

October 25, 2021

Conditions
COVID-19
Interventions
DRUG

Sargramostim

250 μg/vial of sargramostim will be dissolved in 4 mL of physiological saline and 125 μg of which will be administered using inhaler twice daily in approximately 10-15 minutes.

DRUG

Placebo

2 mL of physiological saline will be administered using inhaler twice daily in approximately 10-15 minutes.

Trial Locations (7)

Unknown

IUHW Narita Hospital, Narita

Kanagawa Cardiovascular and Respiratory Center, Yokohama

Japanese Red Cross Society Saitama Red Cross Hospital, Saitama

St. Luke's International Hospital, Chuo-ku

Mishuku Hospital, Meguro-ku

Japanese Red Cross Medical Center, Shibuya-ku

Center Hospital of the National Center for Global Health and Medicine, Shinjuku-Ku

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Nobelpharma

INDUSTRY

NCT04642950 - A Phase II/III Study of Sargramostim | Biotech Hunter | Biotech Hunter